Nettel F, Rodríguez N, Nigro J, González M, Conde A, Muñoa A, Redigonda E, Aguilar G, Elizondo J, Plaquin J, Riley L, Cousin L, Lecuona N, Betanco Ó, Cortés R, Guerrero V

Idioma: Español
Referencias bibliográficas: 184
Paginas: 95-126
Archivo PDF: 241.61 Kb.

FRAGMENTO

La úlcera venosa de los miembros inferiores es una patología frecuente. Los costos que genera en términos de deterioro de calidad de vida, pérdida de capacidad laboral e insumo de recursos médicos, son muy altos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, Meissner MH, et al; American Venous Fsion of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40(6): 1248-52.

2. Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P; American Venous Forum; European Venous Forum; International Union of Phlebology; American College of Phlebology; International Union of Angiology. Updated terminology of chronic venous disorders: the VEINTERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009; 49(2): 498-501.

3. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strengh of recommendatios. BMJ 2008; 336(7650): 924-6.

4. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ; GRADE Working Group. What is “quality of evidence” and why is it important to clinicians? BMJ 2008; 336(7651): 995-8.

5. Guyatt GH, Oxman AD, Kunz R, Falck Ytter Y, Vist GE, Liberati A, Schünemann HJ. GRADE Working Group. Going from evidence to recomendatios. BMJ 2008; 336(7652): 1049-51.

6. Lacour RA, Sala Haedo ME, Sánchez FC, Palopolo MV. Patología venosa crónica. Su repercusión biopsicosocial y laboral. Forum Fl 1998; 3: 1-22.

7. Etcheverry RM, Nettel J, Lis Camilo, et al. Tratamiento de la úlcera venosa. Estudio observacional en centros especializados de Latinoamérica. VENCER. Simposio Pierre Fabre. 23 de Agosto de 2010. Congreso Mundial de la Unión Internacional de Angiología. Buenos Aires.

8. Eklof B, Perrin M, Delis KT, Rutherford RB, et al. Updated terminology of chronic venous disorders: The VEIN-TERM transatlantic interdisciplinary consensus document. J Vascular Surgery 2009; 49(2): 498-501

9. Berard A, Abenhaim L, Platt R, Kahn SR, Steinmetz O. Risk factors for the first-time development of venous ulcers of the lower limbs: the influence of heredity and physical activity. Angiology 2002; 53(6): 647-57.

10. Grzela T, Bialoszewska A. Genetic risk factors of chronic leg ulceration: Can molecular screening aid in the prevention of chronic venous insufficiency complications? Mol Med Report 2010; 3(2): 205-11.

11. Gattringer C, Scheurecker C, Höpfl R, Müller H. Association between venous leg ulcers and sex chromosome anomalies in men. Acta Derm Venereol 2010; 90: 612-5.

12. Zamboni P, Tognazzo S, Izzo M, Pancaldi F, Scapoli GL, Liboni A, Gemmati D. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg 2005; 42: 309-14.

13. Takahashi PY, Chandra A, Cha SS, Crane SJ. A predictive model for venous ulceration in older adults: results of a retrospective cohort study. Ostomy Wound Manage 2010; 56(4): 60-6.

14. Wipke-Tevis DD, Rantz MJ, Mehr DR, Popejoy L, Petroski G, Madsen R, Conn VS, et al. Prevalence, incidence, management, and predictors of venous ulcers in the long-term-care population using the MDS. Adv Skin Wound Care 2000; 13(5): 218-24.

15. Chaby G, Viseux V, Ramelet AA, Ganry O, Billet A, Lok C. Refractory venous leg ulcers: a study of risk factors. Dermatol Surg 2006; 32(4): 512-9.

16. Augey F, Pinet A, Renaudier P. Heart failure and stasis ulcer: A significant association (prospective study of 100 cases). Ann Dermatol Venereol 2010; 137(5): 353-8.

17. Chaby G, Viseux V, Ramelet AA, Ganry O, Billet A, Lok C. Refractory venous leg ulcers: a study of risk factors. Dermatol Surg 2006; 32(4): 512-9.

18. Marston W, Fish D, Unger J, Keagy B. Incidence of and risk factors for iliocaval venous obstruction in patients with active or healed venous leg ulcers. J Vasc Surg 2011.

19. Hjerppe A, Saarinen JP, Venermo MA, Huhtala HS, Vaalasti A. Prolonged healing of venous leg ulcers: the role of venous reflux, ulcer characteristics and mobility. J Wound Care 2010; 19(11): 474, 476, 478.

20. Robertson L, Lee AJ, Gallagher K, Carmichael SJ, Evans CJ, et al. Risk factors for chronic ulceration in patients with varicose veins: a case control study. J Vasc Surg 2009; 49(6): 1490-8.

21. Shiman MI, Pieper B, Templin TN, Birk TJ, Patel AR, Kirsner RS. Venous ulcers: A reappraisal analyzing the effects of neuropathy, muscle involvement and range of motion upon gait and calf muscle function. Wound Reapir Regen 2009; 17(2): 147-52.

22. Darvall KA, Sam RC, Adam DJ, Silverman SH, et al. Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls. J Vasc Surg 2009; 49(5): 1235-41.

23. Bradbury AW, MacKenzie RK, Burns P, Fegan C. Thrombophilia andchronic venous ulceration. Eur J Vasc Endovasc Surg 2002; 24(2): 97-104.

24. Milic DJ, Zivic SS, Bogdanovic DC, Karanovic ND, Golubovic ZV. Risk factors related to the failure of venous leg ulcers to heal with compression treatment. J Vasc Surg 2009; 49(5): 1242-7.

25. Franks PJ, Oldroyd MI, Dickson D, Sharp EJ, Moffatt CJ. Risk factors for leg ulcer recurrence: a randomized trial of two types of compression stocking. Age Ageing 1995; 24(6): 490-4.

26. Abbade LP, Lastoria S, de Almeida Rollo H. Venous ulcer: clinical characteristics and risk factors. Int J Dermatol 2011; 50(4): 405-11.

27. Kecelj Leskovec N, Perme MP, Jezersek M, Mozina J, Pavloviæ MD, Lunder T. Initial healing rates as predictive factors of venous ulcer healing: the use of a laser-based three-dimensional ulcer measurement. Wound Repair Regen 2008; 16(4): 507-12.

28. Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol 2002; 119(6): 1420-5.

29. Jankiæeviæ J, Vesiæ S, Vukiæeviæ J, Gajiæ M, Adamic M, Pavloviæ MD. Contact sensitivity in patients with venous leg ulcers in Serbia: comparison with contact dermatitis patients and relationship to ulcer duration. Contact Dermatitis 2008; 58(1): 32-6.

30. Bahmer FA. Significance of local factors for the development of contact allergic reactions in patients with chronic venous insufficiency. Z Hautkr 1987; 62(23): 1662-4.

31. Sayre EK, Kelechi TJ, Neal D. Sudden increase in skin temperature predicts venous ulcers: a case study. J Vasc Nurs 2007; 25(3): 46-50.

32. Magnusson MB, Nelzén O, Volkmann R. Leg ulcer recurrence and its risk factors: a duplex ultrasound study before and after vein surgery. Eur J Vasc Endovasc Surg 2006; 32(4): 453-61.

33. Gohel MS, Taylor M, Earnshaw JJ, Heather BP, Poskitt KR, Whyman MR. Risk factors for delayed healing and recurrence of chronic venous leg ulcers–an analysis of 1324 legs. Eur J Vasc Endovasc Surg 2005; 29(1): 74-7.

34. McDaniel HB, Marston WA, Farber MA, Mendes RR, Owens LV, Young ML, Daniel PF, et al. Recurrence of chronic venous ulcers on the basis of clinical, etiologic, anatomic, and pathophysiologic criteria and airplethysmography. J Vasc Surg 2002; 35(4): 723-8.

35. Wipke-Tevis DD, Stotts NA. Nutritional risk, status,orum International Ad Hoc Committee for Revi growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18(7): 604-6.and intake of individuals with venous ulcers: a pilot study. J Vasc Nurs 1996; 14(2): 27-33.

36. Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospectivecohort study. Vasc Med 1999; 4(1): 1-7.

37. Ekloff B, Rutherford RB, Bergan JJ, Carpentier Ph, Gloviczki P, Kistner RL, et al. For the American venous Forum’s. International ad hoc commitiee for revision of the CEAP classification. Revision of the CEAP. J Vasc Surg 2004; 40: 1248-52.

38. van Bemmelen PS, Spivack D, Kelly P. Reflux in foot veins is associated with venous toe and forefoot ulceration. J Vasc Surg 2011; 53(2): 394-8.

39. Pastar I, Stojadinovic O, Krzyzanowska A. Attenuation of the Transforming Growth Factor β–Signaling Pathway in Chronic Venous Ulcers. Mol Med 2010; 16(3-4): 92-101.

40. Cantú C, Chiquete E, Duarte M, et al. Estudio multicéntrico INDAGA. Índice tobillo-brazo anormal en población mexicana con riesgo vascular. Rev Med Inst Mex Seguro Soc 2011; 49: 239-46.

41. Fernandez R, Griffiths R. Water for wound cleansing. Cochrane Database Syst Rev 2008; (1): CD003861.

42. European Wound Management Association (EWMA). Position Document: Wound Bed Preparation in Practice. London: MEP Ltd, 2004.

43. Grupo Nacional para el Estudio y Asesoramiento en Úlceras por Presión y Heridas Crónicas (GNEAUPP). Desbridamiento de úlceras por presión y otras heridas crónicas. Doc. Técnico Nº IX. 2005.

44. Flanagan M, Marks-Maran D. The developing speciality of tissue viability. Wound Management. Edinburgh: Churchill Livingstone; 1997, p. 12-5.

45. Granik MS, Jacoby M, Noruthrun S, et al. Wounds 2006; 18(2).

46. Sociedad Argentina de Dermatología. Consenso sobre cicatrización de heridas. 2008.

47. European Wound Management Association (EWMA). Position Document: Identifying criteria for wound infection. London: MEP Ltd, 2005.

48. Thomson PD, Smith DJ. What is infection? Am J Surg 1994; 167(Suppl. 1A): 7S-11S.

49. Percival SL, Bowler PG. Biofilms and Their Potential Role in Wound Healing. Wounds 2004; 16(7).

50. O’Meara S, Al-Kurdi D, Ovington LG. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD003557. DOI: 10.1002/14651858.CD003557.pub2.

51. Grupo nacional para el estudio y asesoramiento en úlceras por presión y heridas crónicas (GNEAUPP). Recomendaciones sobre la utilización de antisépticos en el cuidado de heridas crónicas. Doc VIII. 2002.

52. Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med 2002; 34: 419-27.

53. Trengove NJ, Stacey MC, McGechie DF, Mata S. Qualitative bacteriology and leg ulcer healing. J Wound Care 1996; 5(6): 277-80.

54. Woo K, Ayello E, Sibbald RG. The Edge Effect: Current Therapeutic Options to Advance the Wound Edge. Adv Skin Wound Care 2007; 20(2): 99-117.

55. European Wound Management Association (EWMA). Position Document: Management of wound infection. London: MEP Ltd, 2006.

56. Bowler PG. The 105 bacterial growth guideline: reassessing its clinical relevance in wound healing. Ostomy Wound Manage 2003; 49: 44-53.

57. Frank Ch, Bayoumi I, Westendorp C. Approach to infected skin ulcers. Can Fam Physician 2005; 51: 1352-9.

58. International Working Group on the Diabetic Foot. International consensus on the diabetic foot [CD-ROM]. Brussels: International Diabetes Foundation, May 2003. Crónicas. Doc VIII. 2002.

59. Jull AB, Rodgers A, Walker N. Honey as a topical treatment for wounds. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD005083. DOI: 10.1002/ 14651858.CD005083.pub2.

60. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, Lefrock JL, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39(7): 885-910.

61. Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005486. DOI: 10.1002/14651858.CD005486. pub2.

62. Chambers H, Dumville JC, Cullum N. Silver treatments for leg ulcers: a systematic review. Wound Repair Regen 2007; 15(2): 165-73.

63. Sibbald RG. Topical antimicrobials. Ostomy Wound Manage 2003; 49(Suppl. 5A): 14-8.

64. Documento de Consenso: Conferencia Nacional sobre las úlceras de la extremidad inferior (CONUEI). 2009. ISBN: 978-84-7877-555-2. Disponible en: http:// www.aeev.net/.

65. Stevens DL, Bisno AL, Chambers HF. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-406.

66. World Union of Wound Healing Societies (WUWHS). Principios de las mejores prácticas: Exudado en las heridas y utilidad de los apósitos. Un documento de consenso. London: MEP Ltd; 2007.

67. Grinnell F, Ho Ch, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, inmunoblotting and cell adhesion assays. J Invest Dermatol 1992; 98: 410-8.

68. Ludwig GP, et al. Ratios of activated matrix metailoproteinase- 9 to tissue inhibitor of matriz metalloproteinase- I in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 2002; 10(26): 56.

69. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64.

70. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7(6): 442-52.

71. Agencia de Evaluación de Tecnologías Sanitarias (AETS) Instituto de Salud Carlos III - Ministerio de Sanidad y Consumo «Efectividad de los Apósitos Especiales en el Tratamiento de las Úlceras por Presión y Vasculares» Madrid: AETS - Instituto de Salud Carlos III, Noviembre de 2001.

72. Palfreyman SSJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001103. DOI: 10.1002/14651858.CD001103.pub2.

73. European Wound Management Association (EWMA). Position Document: Wound Bed Preparation in Practice. London: MEP Ltd, 2004.

74. Kantor J, Margolis DJ. Management of leg ulcers. Semin Cutan Med Surg 2003; 22(3): 212-21.

75. Martin TA, Hilton J, Jiang WG, Harding K. Effect of human fibroblast-derived dermis on expansion of tissue from venous leg ulcers. Wound Repair Regen 2003; 11(4): 292-6.

76. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal

77. Robson MC, Phillips TJ, Falanga V, et al. Randomised trial of topically applied Repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 2001; 9(5): 347-52.

78. Robson MC, Phillips LG, Lawrence WT, Bishop JB, Youngerman JS, Hayward PG, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992; 216(4): 401-6; Discussion 406-8.

79. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992; 339(8784): 23-5.

80. Pierce GF, Tarpley JE, Allman RM, Goode PS, Serdar CM, Morris B, et al. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet- derived growth factor BB. Am J Pathol 1994; 145(6): 1399-410.

81. Steed DL. Clinical evaluation of recombinant human platelet- derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21(1): 71-8; Discussion 79-81.

82. Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996; 183(1): 61-4.

83. Falanga V. Advanced treatments for non-healing chronic wounds. World Wide Wounds. 2005. Disponible en: http://www.worldwidewounds.com/2005/april/Falanga/ Advanced-Treatments-Chronic-Wounds.html#ref10

84. Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 2000; 8(5): 347-52.

85. Halabe A, Ingber A, Hodak E, David M. Granulocytemacrophage colony-stimulating factor-a novel therapy in the healing of chronic ulcerative lesions. Med Sci Res 1995; 23: 65-6.

86. Pojda Z, Struzyna J. Treatment of non-healing ulcers with rh- GM-CSF and skin grafts. Lancet 1994; 343: 1100.

87. Jaschke E, Zabernigg A, Gattringer C. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 1999; 38: 380-6.

88. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7(5): 335-46.

89. Marques de la Costa R, Jesus FM, Aniceto C, Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony stimulating factor in chronic leg ulcers. Am J Surg 1997; 173: 165-8.

90. Cullen B, Smith R, McCulloch E, et al. Mechanism of action of Promogran, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002; 10(1): 16-25.

91. Chen WY, Abatangelo G. Functions of hyaluronan in wound repair. Wound Repair Regen 1999; 7(2): 79-89.

92. Wollina U, Schmidt WD, Kronert C, Nelskamp C, Scheibe A, Fassler D. Some effects of a topical collagen-based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations. Int J Low Extrem Wounds 2005; 4: 214-24.

93. Talbot H, Del Mar C, Frangos J, Kumar K, Smart NA, Walters J. Dressings and topical agents containing hyaluronic acid for wound healing. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD007089. DOI: 10.1002/14651858.CD007089.

94. Colletta V, Dioguardi D, Di Lonardo A, et al. A trial to assess the efficacy and tolerability of Hyalofill-F in non-healing venous leg ulcers. J Wound Care 2003; 12(9): 357-60.

95. Taddeucci P, Pianigiani E, Colletta V, Torasso F, Andreassi L, Andreassi A. An evaluation of Hyalofill-F plus compression bandaging in the treatment of chronic venous ulcers. J Wound Care 2004; 13: 202-4.

96. Fray MJ, Dickinson RP, Huggins JP, Occleston NL. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem 2003; 46(16): 3514-25.

97. Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol 2003; 139(4): 510-6.

98. Roeckl Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg 2005; 92: 24-32.

99. Kranke P, Bennett MH, Debus SE, Roeckl-Wiedmann I, Schnabel A. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004123. DOI: 10.1002/ 14651858.CD004123.pub2.

100. Ojingwa JC, Isseroff RR. Electrical stimulation of wound healing. J Invest Dermatol 2002; 36: 1-11.

101. Kloth LC. Electrical stimulation for wound healing: a review of evidence from in vitro studies, animal experiments, and clinical trials. Int J Lower Extrem Wounds 2005; 4: 23-44. 60.

102. Zhao M, Bai H, Wang E, Forrester JV, McCaig CD. Electrical stimulation directly induces pre-angiogenic responses in vascular endothelial cells by signaling through VEGF receptors. J Cell Sci 2004; 117(Pt. 3): 397-405.

103. Houghton PE, Kincaid CB, Lovell M, et al. Effect of electrical stimulation on chronic leg ulcer size and appearance. Phys Ther 2003; 83: 17-28.

104. Cullum N, Nelson EA, Flemming K, Sheldon T. Systematic reviews of wound care management: beds, compression, laser therapy, therapeutic ultrasound, electrotherapy, and electromagnetic therapy. Health Technol Assess 2001; 5(9): 1-221.

105. Flemming K, Cullum N. Therapeutic ultrasound for venous leg ulcers. Cochrane Database Syst Rev 2000; 4: CD00180.

106. Wills EE, Anderson TW, Beattie BL, Scott A. A randomized placebo-controlled trial of ultraviolet light in the treatment of superficial pressure sores. J Am Geriatr Soc 1983; 31: 131-3.

107. Dodd HJ, Sarkany I, Gaylarde PM. The short-term benefit and long-term failure of ultraviolet light in the treatment of venous leg ulcers. Br J Dermatol 1989; 120: 809-18.

108. Banwell P, Teot L. Topical negative pressure (TNP): the evolution of a novel wound therapy. J Tissue Viability 2006; 16: 16-24.

109. European Wound Management Association (EWMA). Documento de posicionamiento: La presión negativa tópica en el tratamiento de heridas. Londres: MEP Ltd; 2007.

110. Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD001898. DOI: 10.1002/ 14651858.CD001898.pub2.

111. Woo K, Ayello E, Sibbald RG. The Edge Effect: Current Therapeutic Options to Advance the Wound Edge. Adv Skin Wound Care 2007; 20(2): 99-117.

112. 112 Douglas WS, Simpson NB. Guidelines for the management of chronic venous leg ulceration: report of a multidisciplinary workshop. Br J Dermatol 1995; 132: 446-52.

113. Kirsner RS, Falanga V. Techniques of split-thickness skin grafting for lower extremity ulcerations. J Dermatol Surg Oncol 1993; 19: 779-83.

114. Kirsner RS, Matta SM, Falanga V, Kerdel FA. Split-thickness skin grafting of leg ulcers. J Dermatol Surg 1995; 21: 701-3.

115. Teh BT. Why skin grafts fail. Plast Reconstr Surg 1979; 49: 323-30.

116. Ahnlide I, Bjellerup M. Efficacy of pinch grafting in leg ulcers of different aetiologies. Acta Derm Venereol 1997; 77: 144-5 [PMID: 9111828].

117. Limova M, Mauro T. Treatment of leg ulcers with cultured epithelial autografts: treatment protocol and five year experience. Wounds 1995; 7: 170-80.

118. Phillips TJ, Kehinde O, Green H, Gilchrest BA. Treatment of skin ulcers with cultured epidermal allografts. J Am Acad Dermatol 1989; 21: 191-9 [PMID: 2768568].

119. Davis JS. Skin transplantation. With a review of 550 cases at the Johns Hopkins Hospital. JHH Report 1910; 15: 307.

120. Ward DJ, Bennett JP, Burgos H, et al. The healing of chronic venous leg ulcers with prepared human amnion. Br J Plast Surg 1989; 42: 463-7.

121. Hernández CM. Tratamiento de las úlceras vasculares con membranas amniocoriales. Angiología 1993; 45: 112-6.

122. Bobrovsky E, et al. Uso de membrana amniótica homóloga liofilizada en la reparación de úlceras venosas graves. Revista Flebología 2008; 33(1): 14-6.

123. Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limbs compression bandages? Am J Med 2000; 109(1): 15-19.

124. Flanagan M. Wound measurement: can it help us to monitor progression to healing? J Wound Care 2003; 12(5): 189-94.

125. Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol 2000; 142(5): 960-4.

126. Donohue K, Falanga V. Healing rate as a prognostic indicator of complete healing: A reappraisal. Wounds 2003; 15: 71–6.

127. Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol 2002; 119: 1420-5.

128. Yager DR, Chen SM, Ward SI, et al. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen 1997; 5: 23-32.

129. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous plateletderived wound healing factors (PDWHF). Department of Surgery, University of Minnesota, Minneapolis. Ann Surg 1986; 204(3): 322-30.

130. Pierce GF, Mustoe TA, Lingelbach J. Platelet derived growth factor and transforming growth factor beta enhance tissue repair activities by unique mechanisms. Department of Surgery, Jewish Hospital, Washington University Medical Center, St. Louis, Missouri 63110. J Cell Biol 1989; 109: 42-3.

131. Habenicht AJ, Salbach P, Janssen Timmen U, Blattner C, Schettler Platelet - derived growth factor - a growth factor with an expanding role in health and disease. Medizinische Universitatsklinik, Abteilun Endo krinologie Stoffwechsel, Heidelberg. Klin Wochenschr 1990 Jan; 19; 68(2): 53-9.5.2.4.

132. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. LT Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. AU: Department of Surgery, University of Minnesota, Minneapolis. Surg Gynecol Obstet 1990; 170 (1): 56-60. 5.2.5

133. Knighton DR, Phillips GD, Fiegel VD. Wound Healing angiogenesis: indirect stimulation by basic fibroblast growth factor. Department of Surgery, University of Minnesota, Minneapolis 55455. J Trauma 1990; 30 (12 Suppl.): S134-S144.

134. Mustoe TA, Pierce GF, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. Department of Experimental Pathology, Amgen Inc., Thousand Oaks. California 91320. J Cell Biochem 1991; 45(4): 319-26.

135. Bobrovsky EO, et al. Ulcer healing and platelet growth factor. International Angiology. GE4. 6-12 2009; 28(4; Suppl.1): 86.

136. Bobrovsky EO, et al. Cura de úlceras y factores de crecimiento plaquetario. Revista Flebología 2010; 36(1): 7-17.

137. Brizzio EO. Las vendas y su técnica de aplicación 2006, sección IV, bases físicas de la compresión, p. 45-6.

138. Callam MJ, Harper DR, Daie JJ, Ruckley CV. Chronic ulcer of the leg; clinical history. Br Med J (Clin RES. Ed.) 1987; 294 (6584): 1389-91.

139. Brizzio EO. Las vendas y su técnica de aplicación 2006, sección VI, p. 57-131.

140. Van Hecke A, Grypdonck M, Defloor T. A review of why patients wiht leg ulcers do not adhere to treatment. J Clin Nurs 2009; 18(3): 337-49.

141. Van Hecke A, Grypdonck M, Defloor T. Intervetions to enhance patient compliance with leg ulcer treatment. A review of literature. J Clin Nurs 2008; 17(1): 29-39.

142. Compresión para las úlceras venosas de las piernas. Cullum N, Nelson EA, Fletcher AW, Sheldon TA. Reproducción de una revisión Cochrane, traducida y publicada en La Biblioteca Cochrane Plus, 2008, Número 2.

143. 143 Simka M, Majewski E. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy. Am J Clin Dermatol 2003; 4(8): 573-81.

144. Harrison M, Graham I, Lorimer K, et al. Leg-ulcer care in the community, before and after implementation of an evidence-based service. CMAJ 2005; 172: 1447-52.

145. Gohel MS, Davies AH. Pharmacological treatment in patients with C4, C5 and C6 venous disease. Phlebology 2010; 25(Suppl. 1): 35-41.

146. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30(2): 198-208.

147. Boyle P, Diehm C, Robertson C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int Angiol 2003; 22(3): 250-62.

148. Smith PC. Daflon 500 mg and venous leg ulcer: new results from a meta-analysis. Angiology 2005; 56(Suppl. 1): S33-S39.

149. Chaby G. Management of leg ulcers. Rev Prat 2010; 60(7): 970-8.

150. Nettel J. Estudio Vencer, presentado como comunicación oral en el congreso UIA, Bs As, Argentina, 2010 [In press].

151. Marrocco CJ, Atkins MD, Bohannon WT, Warren TR, Buckley CJ, Bush RL. Ablación endovenosa en el trata miento de la insuficiencia venosa crónica y úlceras venosas. World J Surg 2010; 34(10): 2299-304.

152. Partsch H. Hemodynamic patterns of venous reflux in patient with leg uklcers. EWMA J 2009; 9(1): 33-8.

153. Guarnera G. Combined superficial and deep vein reflux in venous ulcers: operative strategy. EWMA J 2009; 9(1); 40-3.

154. Nelzen O. Prospective study of safety, patient satisfaction and leg ulcer healing following saphenous and subfascial endoscopic perforator surgery. Br J Surg 2000; 87: 86-91.

155. Nelzen O. The role of incompetent perforator. EWMA J 2009; 9(1): 26-31.

156. Bergan J, Luigi P. The Vein Book. Elsevier Inc.; 2006.

157. Walsh JC, Bergan JJ, Beeman S, et al. Femoral venous reflux abolished by greater saphenous vein stripping. Ann Vasc Surg 1994; 8: 566-70.

158. Sales OM, Bilof ML, Petrillo KA, et al. Correction de lower extremity deep incompetence by ablation of superficial venous reflux. Ann Vasc Surg 1996; 10: 186-9.

159. Nicolaides AN. Investigation of chronic venous insufficiency. A consensus statement. Circulation 2000; 102: 126, 163.

160. Barwell JR, Deacon J, Harvey K, et al. Comparison of surgery and compression alone in chronic venous ulceration (ESCHAR study) randomized controlled trial. The Lancet 2004; 363: 1854-59.

161. Guarnera G. The venous ulcer and the superficial venous reflux. Int J Low Extrem Wounds 2004; 3(4): 198- 200.

162. Cabrera J, Redondo P, Becerra A, Garrido C, Cabrera J Jr., Garcia-Olmedo MA, Sierra A, et al. Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers. Arch Dermatol 2004; 140(6): 667-73.

163. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med 2006; 355(5): 488-98.

164. Obermayer A, Gostl K, Walli G, Benesch T. Chronic venous leg ulcers benefit from surgery: long-term results from 173 legs. J Vasc Surg 2006; 44(3): 572-9.

165. Kjaer ML, Jorgensen B, Karlsmark T, Holstein P, Simonsen L, Gottrup F. Does the pattern of venous insufficiency influence healing of venous leg ulcers after skin transplantation? Eur J Vasc Endovasc Surg 2003; 25: 562-7.

166. Gohel MS, Barwell JR, Taylor M, Chant T, Foy C, Earnshaw JJ, Heather BP, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. Br Med J 2007; 335: 83.

167. Tripathi R, Sieunarine K, Abbas M, Durrani N. Deep venous valvereconstruction for non–healing ulcers: Techniques and results. ANZ J Surg 2004; 74: 34-9.

168. Zamboni P, Cisno C, Marchetti P, Mazza P, Fogato L, Carandina S, et al. Minimally invasive surgical management of primary venousulcers vs compression treatment: A randomized clinical trial. Eur J Vasc Endovasc Surg 2003; 25: 313-8.

169. Van Gent WB, Hop WC, van Praag MC, Mackaay AJ, de Boer EM, Wittens CH. Conservative versus surgical treatment of venous leg ulcers: a prospective, randomized, multicenter trial. J Vasc Surg 2006; 44(3): 563-71.

170. Obermayer A, Göstl K, Walli G, Benesch T. Chronic venous leg ulcers benefit from surgery: long-term results from 173 legs. J Vasc Surg 2006; 44(3): 572-9.

171. Obermayer A, Göstl K, Partsch H, Benesch T. Venous reflux surgery promotes venous leg ulcer healing despite reduced ankle brachial pressure index. Int Angiol 2008; 27(3): 239-46.

172. Gohel MS, Barwell JR, Taylor M, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ 2007; 335(7610): 83.

173. Darvall KA, Bate GR, Adam DJ, et al. Ultrasound-guided foam sclerotherapy for the treatment of chronic venous ulceration:a preliminary study. Eur J Vasc Endovasc Surg 2009; 38(6): 764-9.

174. O’Hare JL, Earnshaw JJ. Randomised clinical trial of foam sclerotherapy for patients with a venous leg ulcer. Eur J Vasc Endovasc Surg 2010; 39(4): 495 (sacados de Parsch).

175. Stuart WP, Adam DJ, Allan PL, Ruckley CV, Bradbury AW. The relationship between the number, competence, and diameter of medial calf perforating veins and the clinical status in healthy subjects and patients with lowerlimb venous disease. J Vasc Surg 2000; 32(1): 138-43.

176. Gloviczki P, Bergan JJ, Rhodes JM, Canton LG, Harmsen S, Ilstrup DM, et al. Mid-term results of endoscopic perforator vein interruption for chronic venous insufficiency: lessons learned from the North American subfascial endoscopic perforator surgery registry. The North American Study Group. J Vasc Surg 1999; 29: 489-502.

177. Gloviczki P, Bergan JJ, Menawat SS, Hobson RW 2nd, Kistner RL, Lawrence PF, et al. Safety, feasibility, and early efficacy of subfascial endoscopic perforator surgery: a preliminary report from the North American Registry. J Vasc Surg 1997; 25: 94-105.

178. Elias S. Percutaneous ablation of perforating veins. In: Gloviczki P (ed.). Handbook of venous disorders: guidelines of the American Venous Forum. 3rd. ed. London: Hodder Arnold; 2009, p. 536-44.

179. Proebstle TM, Herdemann S. Early results and feasibility of incompetent perforator vein ablation by endovenous laser treatment. Dermatol Surg 2007; 33: 162-8.

180. Masuda EM, Kessler DM, Lurie F, Puggioni A, Kistner RL, Eklof B, et al. The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores. J Vasc Surg 2006; 43: 551-6.

181. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011: 53(16S).

182. Bottini O, Gural Romero O, Bercovich J, Morales M, La Mura Ricardo. Esclerosis con láser ecoasistido de perforantes (ELEAP). Rev Fórum de Flebología y Linfología 2006; 8(1): 5-9.

183. Soracco J, Lopez Dámbola J, Ciuycci J. Láser endovascular en la insuficiencia venosa superficial. Rev Panam de Flebología y Linfología 2000; 38.

184. Raju S, Berry MA, Neglen P. Transcommissural valvuloplasty:Technique and results. J Vasc Surg 2000; 32: 69-76.